UNSPSC 51282942: Rosoxacin

This classification denotes a quinolone antibiotic with the molecular formula C17H14N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3Y1OT3J4NW, chemically known as 3-quinolinecarboxylic acid, 1-ethyl-1,4-dihydro-4-oxo-7-(4-pyridinyl)- but generally known as rosoxacin, which bears US NIH Compound Identifier 287180. European Medicines Agency schedules Rosoxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10389MIG.

UNSPSC 51282942 Rosoxacin, a Commodity code, does not map to the actual state and local procurement activity posted under it. The source shows four recent opportunities tagged to this code — for naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer pharmaceutical prescriptions (Texas HHS), medical and first aid supplies for emergency response (City of Tampa), and generic pharmaceuticals and OTC products via cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations concern rosoxacin specifically, a fluoroquinolone antibiotic. The opportunities instead reflect broad procurement of emergency medical supplies, pharmaceutical distribution infrastructure, and OTC products across health and safety agencies. Issuing bodies include county health departments, state health and human services agencies, municipal fire departments, and cooperative purchasing consortia serving multiple jurisdictions. The disconnect between the code's nominal scope and the actual work being solicited suggests the code is not actively used for its intended commodity classification in state and local procurement, or the tagging reflects data entry error rather than substantive rosoxacin procurement activity.

Recent activity concentrates in Florida, Texas, Minnesota, and Oregon, driven primarily by cooperative purchasing arrangements and municipal emergency services procurement. The Seminole County IFB (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually; the City of Tampa's IFB (26P00145, due March 13, 2026) covered 169 line items of medical and first aid supplies totaling $700,000, with a 5% bid discount set-aside for certified Small Local Business Enterprises; and the Minnesota Multistate Cooperative Purchasing Alliance RFP (S1070000015802, due March 26, 2026) sought manufacturers of generic pharmaceuticals and OTC products for distribution across multiple states. The Texas HHS RFI (HHS0017013, posted April 3, 2026) served as an exploratory tool to inform future direct-to-manufacturer pharmacy contracting. No recent opportunities specifically named rosoxacin procurement.